Consumer Food Purchases After GLP-1 RA InitiationConsumer Food Purchases After GLP-1 RA Initiation
This cross-sectional study examines whether initiating glucagon-like peptide-1 receptor agonists (GLP-1RAs) for treatment is associated with changes in the nutritional quality and processing level of supermarket purchases. This cross-sectional study examines whether initiating glucagon-like peptide-1 receptor agonists (GLP-1RAs) for treatment is associated with changes in the nutritional quality and processing level of supermarket purchases.
GLP-1 Therapy May Offer Added Benefit in IBD Beyond Weight LossGLP-1 Therapy May Offer Added Benefit in IBD Beyond Weight Loss
(MedPage Today) — LAS VEGAS — GLP-1-based therapies may offer benefits in inflammatory bowel disease (IBD) that extend beyond their metabolic indication, according to two poster presentations at the Crohn’s & Colitis Congress. In a large… (MedPage Today) — LAS VEGAS — GLP-1-based therapies may offer benefits in inflammatory bowel disease (IBD) that extend Read More
Why I’m Choosing Not to Take GLP-1s, Even Though Everyone Expects Me ToWhy I’m Choosing Not to Take GLP-1s, Even Though Everyone Expects Me To
I’m a candidate for the meds, but they’re not for me—at least for now. I’m a candidate for the meds, but they’re not for me—at least for now.
Hormone therapy combined with tirzepatide linked to greater weight loss after menopauseHormone therapy combined with tirzepatide linked to greater weight loss after menopause
A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling Read More
This new antibody may stop one of the deadliest breast cancersThis new antibody may stop one of the deadliest breast cancers
Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of the disease. An experimental antibody targets a protein that fuels tumor growth and shuts down immune defenses, effectively turning the immune system back on. In early tests, the treatment slowed tumor growth, reduced lung metastases, and destroyed chemotherapy-resistant cancer cells.
Progression-free survival prolonged with sacituzumab govitecan plus pembrolizumab in triple-negative breast cancerProgression-free survival prolonged with sacituzumab govitecan plus pembrolizumab in triple-negative breast cancer
For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus pembrolizumab yields significantly longer progression-free survival than chemotherapy plus pembrolizumab, according to a study published in the Jan. 22 issue of the New England Journal of Medicine.
Carbon-ion therapy offers nonsurgical option for early breast cancer treatmentCarbon-ion therapy offers nonsurgical option for early breast cancer treatment
For many women with early breast cancer, surgery is effective but life-altering. New five-year data from the National Institutes for Quantum Science and Technology (QST) suggest that a precisely targeted, high-energy particle therapy may allow some patients to avoid surgery without compromising oncologic outcomes.
Breast cancer study reveals synergistic effect of CDK2 and CDK4/6 combination therapyBreast cancer study reveals synergistic effect of CDK2 and CDK4/6 combination therapy
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature Communications, identifies a powerful strategy to overcome drug resistance in breast cancer by simultaneously targeting two key cell-cycle regulators, CDK2 and CDK4/6.
STAT+: Pharmalittle: We’re reading about Europe’s pharma supply chain, stopping GLP-1 drugs, and moreSTAT+: Pharmalittle: We’re reading about Europe’s pharma supply chain, stopping GLP-1 drugs, and more
Good morning, everyone, and welcome to the middle of the holiday-shortened week on this side of the pond. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we are firing up Read More
GLP-1 medications: A comprehensive overviewGLP-1 medications: A comprehensive overview
With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes. With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.